C50
Conditions
Interventions
Group 1: This prospective, non-interventional, observational health services research study examines the implementation of a digitally supported integrated care system for structured oncological after
Sponsors
Medizinische Universität Graz
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Female Patients: - Primary disease or recurrence of a diagnosed hormone receptor-positive, HER2-negative breast cancer (C50) - Curative treatment plan with no indication for (neo-)adjuvant chemotherapy - AJCC tumour stage I - Completion of treatment: surgery, radiotherapy - Written consent from patients to participate in OnkoMobil Steiermark (relates to the research component) - Sufficient ability of the patient and/or their personal support network to communicate digitally - Sufficient cognitive abilities (including adherence) - Willingness to participate in the OnkoMobil Steiermark project - Resident in Styria, registered with the Austrian social security system - Long-term follow-up: Willingness to participate in the study over an extended period (for at least 5 years following surgery) - Technical requirements: Access to a smartphone, tablet or PC with internet access; basic digital literacy or willingness to receive training - Language: Sufficient command of spoken and written German Primary care providers: - doctors
Exclusion criteria
Exclusion criteria: Female patients: - Metastatic breast cancer or untreated breast cancer - Severe mental or cognitive impairments (e.g. dementia, severe depression, psychosis) - Active other tumour diseases or ongoing follow-up care due to other tumour diseases - Life expectancy of less than 12 months - No digital access (lack of infrastructure or unwillingness to use digital formats) - Participation in an interventional trial with potential interference - Planned change of residence from Styria within the next 12 months - Acute, severe comorbid condition that makes participation in a long-term study unreasonable Primary care providers: - No exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participation of female patients in the planned patient pathway (as per the aftercare pathway) at the end of the project (analysis of patient data as shown on the dashboard) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Key performance indicators from the care pathway (prospective) - Patient-reported outcomes (PROMs) (OnkoMobil Side Effects Questionnaire_V1, EORTC QLQ-C30, EORTC QLQ-BR42, Patient’s Global Impression of Treatment Tolerability (PGI-TT)) - Patient-reported outcomes (PREMs) (Patient Satisfaction with Cancer-related Care (PSCC) Questionnaire, System Usability Scale (SUS)) - Primary care providers’ expectations/experiences (assessed via interviews and focus groups) | — |
Countries
Austria
Contacts
Public ContactMagdalena Hoffmann
Medizinische Universität Graz
Outcome results
None listed